- Signaling Pathways
- Antibody-Drug Conjugate/ADC Related
- Antibody-Drug Conjugates (ADCs)
Antibody-Drug Conjugates (ADCs)
Antibody-Drug Conjugates
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.
All three component parts of an ADC, the antibody, the cytotoxic agent, and the linker that joins them, are critical elements in its design. The antibody moiety should be specific for a cell surface target molecule that is selectively expressed on cancer cells, or overexpressed on cancer cells relative to normal cells. The payload of an ADC must be highly cytotoxic so that it can kill tumor cells at the intracellular concentrations achievable following distribution of the ADC into solid tumor tissue, and because only a limited number of payloads can be linked to an antibody molecule (typically an average of 3-4 payloads per antibody) without severely compromising its biophysical and pharmacokinetic properties. The cytotoxic compounds include derivatives of calicheamicin, a class of highly cytotoxic enediyne antibiotics which kill cells by causing DNA double-strand breaks, and derivatives of the potent antimitotic microtubule-disrupting agents, dolastatin 10 (auristatins) and maytansine.
The third vital component of an ADC is the linker that forms a chemical connection between the payload and the antibody. The linker should be sufficiently stable in circulation to allow the payload to remain attached to the antibody while in circulation as it distributes into tissues (including solid tumor tissue), yet should allow efficient release of an active cell-killing agent once the ADC is taken up into the cancer cells. Linkers can be characterized as either cleavable, or as non-cleavable.
All Product Categories
-
Antibody-Drug Conjugates (ADCs) Related Products (160)
Related Products (160)
-
ZW-251
0 ImagesCat. No.: HY-185742ZW-251 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) with topoisomerase-I inhibitory activity. ZW-251 induces cytotoxicity, penetrates tumor spheroids, exerts bystander cytotoxicity, and inhibits tumor growth in hepatocellular carcinoma models. ZW-251 can be used for the research of hepatocellular carcinoma. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-CCL2 (Carlumab)-SPDB-DM4
0 ImagesCat. No.: HY-171681Anti-CCL2 (Carlumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with the linker SPDB (HY-12448) and the tubulin inhibitor DM4 (HY-12454). The ADC toxic molecule and linker part are sulfo-SPDB-DM4 (HY-101141). Anti-CCL2 (Carlumab)-SPDB-DM4 can be used in cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ADC Control Human IgG1(D356E/L358M)-LNK4 (DAR8)
0 ImagesCat. No.: HY-185774ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR8) is a control ADC with a drug-to-antibody ratio (DAR) of 8, consisting of Human IgG1 (D356E/L358M) kappa, Isotype Control (HY-P990100), which does not specifically bind to FRα, and LNK4-S (HY-170400). ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR8) serves as the isotype control for Farletuzumab-LNK4-S (DAR8) (HY-185773). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38
0 ImagesCat. No.: HY-171684Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704). The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057). Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38 can be used in cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Trastuzumab deruxtecan (DAR2)
0 ImagesCat. No.: HY-138298BCAS No.: 1826843-81-5Synonyms: T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)Trastuzumab deruxtecan (DAR2) (T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 2. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Farletuzumab-LNK4-S (DAR4)
0 ImagesCat. No.: HY-185773AFarletuzumab-LNK4-S (DAR4) is an antibody-drug conjugate (ADC) with a drug-to-antibody ratio of 4. Farletuzumab-LNK4-S (DAR4) is prepared by conjugating the anti-FRα antibody Farletuzumab (HY-P99153) with LNK4-S (HY-170400). Farletuzumab-LNK4-S (DAR4) can be used in cancer-related research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- Anetumab-MMAE
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Gemtuzumab ozogamicin (solution)
0 ImagesCat. No.: HY-109539ACAS No.: 220578-59-6Gemtuzumab ozogamicin (solution) is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-SLC34A2 (Lifastuzumab)-McMMAF
0 ImagesCat. No.: HY-171737Anti-SLC34A2 (Lifastuzumab)-McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part McMMAF (HY-15578). Anti-SLC34A2 (Lifastuzumab)-McMMAF induces apoptosis and can be used in cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Farletuzumab-LNK4-S (DAR8)
0 ImagesCat. No.: HY-185773Farletuzumab-LNK4-S (DAR8) is an antibody-drug conjugate (ADC) with a drug-to-antibody ratio of 8. Farletuzumab-LNK4-S (DAR8) is conjugated from the anti-FRα antibody Farletuzumab (HY-P99153) and LNK4-S (HY-170400). Farletuzumab-LNK4-S (DAR8) can be used in cancer-related research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-CCL2 (Carlumab)-McMMAF
0 ImagesCat. No.: HY-171682Anti-CCL2 (Carlumab)-McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part are McMMAF (HY-15578). Anti-CCL2 (Carlumab)-McMMAF induces apoptosis and can be used in cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Elfetabart drozuntecan
0 ImagesCat. No.: HY-185683CAS No.: 3061153-84-9Synonyms: DB-1311; BNT324Elfetabart drozuntecan (DB-1311; BNT324) is an antibody-drug conjugate (ADC) targeting B7H3. Elfetabart drozuntecan conjugates a humanized anti-B7H3 IgG1 monoclonal antibody with a topoisomerase I inhibitor via a cleavable linker. Elfetabart drozuntecan exerts antitumor activity in solid tumors. Elfetabart drozuntecan can be used for the research of advanced/metastatic solid tumors. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- DEDN6526A
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
MEDI4276
0 ImagesCat. No.: HY-177710MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in subdomains 2 and 4 of the HER2 ecto-domain. MEDI4276 is composed of MEDI4276 Antibody (HY-P991238) and a cytotoxic payload AZ1508 (HY-128962) linked through site-specific coupling. MEDI4276 exhibits antitumor activity. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1
0 ImagesCat. No.: HY-171735Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the linker SMCC (HY-42360) and the the cytotoxic microtubule inhibitor DM1 (HY-19792). The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070). Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 can be used in the research of cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4
0 ImagesCat. No.: HY-171736Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated with the linker SPDB (HY-12448) and the tubulin inhibitor DM4 (HY-12454). The ADC toxic molecule and linker part are sulfo-SPDB-DM4 (HY-101141). Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 can be used in cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
AZD5335
0 ImagesCat. No.: HY-188120AZD5335 is an ADC targeting FRα, with an IC50 of 10.6 nM against human FRα. AZD5335 specifically binds to FRα, mediates internalization and trafficking to lysosomal compartments, while delivering a topoisomerase I inhibitor payload that traps TOP1-DNA cleavage complexes. AZD5335 induces DNA damage response via the ATR, ATM, Chk1 and Chk2 signaling pathways, and increases the levels of phosphorylated KAP1, phosphorylated RPA, phosphorylated γH2AX, as well as PARP cleavage. AZD5335 exhibits bystander cytotoxicity against FRα-negative cells co-cultured with FRα-expressing cells. AZD5335 induces potent and durable responses and complete regression in ovarian cancer models, including models with low FRα expression and models resistant to Elahere, with enhanced efficacy when combined with Carboplatin, Bevacizumab or poly (ADP-ribose) polymerase inhibitors. AZD5335 can be used for ovarian cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ADC Control Human IgG1-vcMMAE (DAR8)
0 ImagesCat. No.: HY-185830ADC Control Human IgG1-vcMMAE (DAR8) is an antibody-drug conjugate (ADCs), serving as an isotype control for ADC human IgG1-vcMMAE, and inhibits tubulin polymerization. The antibody moiety of ADC Control Human IgG1-vcMMAE (DAR8) is Human IgG1 kappa, Isotype Control (HY-P99001), while the cytotoxic payload and linker moiety are VcMMAE (HY-15575). ADC Control Human IgG1-vcMMAE can be used in cancer-related research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ADC Control Human IgG1-rezetecan (DAR4)
0 ImagesCat. No.: HY-185761A -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Trastuzumab envedotin
0 ImagesCat. No.: HY-172820Synonyms: DP303cTrastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -